Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$127.66MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael G. Raab
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 489
- Beta
- 0.68
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.06
Financials
Revenue
$127.66M+203.9%Net Income
$-737.0KEBITDA
$4.02MFree Cash Flow
$2.17MEPS (diluted)
$-0.00Shares Outstanding (diluted)
250.01M+428.1%Operating Expenses
$119.09MCash & Debt
$285.34MRevenue by Segment (annual)
$657.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $407.32M | $-61.60M | $-0.26 |
| 2024 | $333.62M | $-39.14M | $-0.17 |
| 2023 | $124.46M | $-66.07M | $-0.30 |
| 2022 | $52.16M | $-67.21M | $-0.42 |
| 2021 | $10.10M | $-158.16M | $-1.52 |
| 2020 | $7.57M | $-94.31M | $-1.05 |
| 2019 | $5.28M | $-94.94M | $-1.47 |
| 2018 | $2.61M | $-91.30M | $-1.62 |
| 2017 | $42.00M | $-64.34M | $-1.36 |
| 2016 | $24.03M | $-112.39M | $-2.80 |
| 2015 | $24.03M | $-29.62M | $-1.29 |
| 2014 | $31.62M | $-3.21M | $-0.17 |
| 2013 | $28.93M | $-6.56M | $-0.49 |
| 2012 | $5.41M | $-9.79M | $-0.73 |
Valuation
ARDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (23)
- Newsmarketbeat.com·22h ago·Positive
Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles Ardelyx NASDAQ: ARDX expects to reach profitability in 2027 as it works to sustain growth for IBSRELA while addressing insurance hurdles that have slowed prescription fulfillment, executives said at the Jefferies Healthcare conference in London.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Ardelyx: Upgrading To Hold After Q3, But Risks Still Dominate Ardelyx is upgraded to 'Hold' after a 40% stock decline, despite no fundamental change in its story. IBSRELA drives growth, but SG&A intensity, limited XPHOZAH contribution, and tenapanor concentration constrain upside. DCF model yields a $4.90/share valuation, but 72.6% of the value depends on uncertain terminal assumptions beyond 2034.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Ardelyx, Inc. (ARDX) Q3 2026 Earnings Call Transcript Ardelyx, Inc. (ARDX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Negative
What Ardelyx (ARDX) Said on Its Q3 Earnings Call Ardelyx NASDAQ: ARDX reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for dialysis-focused drug XPHOZAH.
View source ↗ - Newszacks.com·19d ago·Neutral
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·19d ago·Negative
Ardelyx (ARDX) Reports Break-Even Earnings for Q3 Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Positive
… schedule in Phase 3 Clinical Trial in CIC Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Ardelyx: Revisiting The Thesis 2 Years On, I'm Surprised At Lack Of Progress Ardelyx, Inc. maintains a Hold rating as revenue growth slows and reimbursement headwinds persist, despite nearly $500m in annual revenue. 2026 guidance for IBSRELA was cut to $350–$370m, and XPHOZAH faces material Medicare reimbursement challenges, dampening growth expectations. Profitability is targeted for 2027, but over-reliance on tenapanor and lack of pipeline diversification raise strategic concerns.
View source ↗ - Newsglobenewswire.com·30d ago·Negative
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated
View source ↗ - Newsgurufocus.com·33d ago·Neutral
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDXPR NewswireNEW YORK, Oct. 20, 2026NEW YORK, Oct. 20, 2
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026 WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Tuesday, November 3, 2026, at 4:30 p.m.
View source ↗ - Newsglobenewswire.com·41d ago·Negative
… Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C WALTHAM, Mass. , Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastr…
View source ↗ - Newszacks.com·46d ago·Neutral
New Strong Sell Stocks for October 7th ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes
View source ↗ - Newsnewsfilecorp.com·52d ago·Positive
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX) Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX) breached their fiduciary duties owed to the Company and its shareholders.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year
View source ↗ - Newsbusinesswire.com·62d ago·Neutral
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX LOS ANGELES--(BUSINESS WIRE)---- $ARDX--Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX.
View source ↗ - Newsmarketbeat.com·62d ago·Negative
Ardelyx Targets $500M Revenue This Year, Profitability by 2027 Ardelyx NASDAQ: ARDX expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event.
View source ↗ - Newsbusinesswire.com·64d ago·Negative
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ARDX--ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Ardelyx to Participate in Upcoming Investor Conferences WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $0.03 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.00 vs $-0.02beat
- Thu, Aug 6$-0.07 vs $-0.07miss
- Thu, Apr 30$-0.15 vs $-0.13miss
- Thu, Feb 19$0.02 vs $0.02beat
- Thu, Oct 30$-0.00 vs $-0.06beat
- Mon, Aug 4$-0.08 vs $-0.13beat
Estimates and results for ARDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARDX officers and directors.
- Bought
- $1.9m
- Sold
- $3.1m
1 trade
59 trades
- Hohenleitner Susansold
- Reilly Joseph Jamessold
- Reilly Joseph Jamessold
- Bishop John Esold
- Bishop John Esold
- Brady James Parkersold
- Brady James Parkersold
- Foster Eric Duanesold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
